Cancer Biology Program

癌症生物学：摘要 癌症生物学(CB)计划代表了堪萨斯大学癌症大学的基础科学倡议 中心(KUCC)，由分子、生化、模式生物和基于细胞的成员利用统一 研究癌细胞异常行为的方法。CB的科学目标是支持KUCC的 通过识别定义正常和肿瘤细胞生长的分子机制来确定战略计划 并描述与肿瘤生长和进展有关的细胞、分子、途径和过程， 它们可以作为有用的生物标记物或作为癌症预防和治疗的新细胞靶点， 尤其是对KUCC集水区很重要的肿瘤。为了实现这一点，CB的目标是催化 促进基本发现的合作，这些发现可以从长椅到床边转换。 CB有46个正式成员和14个准成员，代表四个校区：堪萨斯大学医学院 KUMC(67%)，堪萨斯-劳伦斯大学(KU-L)(10%)，儿童慈善(CM)(5%)，以及 斯托尔斯医学研究所(斯托尔斯)(18%)。2020年，CB在癌症相关领域获得了超过900万美元的收入， 同行评议的资助，其中120万美元来自NCI，690万美元来自NIH的其他机构。从2016年开始- 2020年，成员发表了880篇与癌症相关的同行评议论文。在这些出版物中，13%是在 高影响力期刊(JIF&GT；10)，所有880种出版物的平均影响系数为6.1。由于续订了 CCSG在2017年，CB计划的凝聚力和集成度有所提高，21%的出版物在 方案间互动产生的供资周期(2016年为20%)和29%来自方案内互动 程序性互动(高于2016年的21%)。CB成员很好地融入了国家和 国际科学界：一半以上的出版物(51%)，包括来自其他国家的作者 23%的人包括来自NCI指定的其他癌症中心的作者。 CB由Kristi Neufeld(KU-L)、林恒(Stowers)、Sufi Thomas(KUMC)和Tomoo Iwakuma共同领导 (Cm)，他们带来了细胞生物学、干细胞生物学、生物化学、翻译 研究、领导经验和多元化的机构代表。施里坎特·阿南特是副主任 为了基础科学。CB领导层采用各种机制来促进方案内和方案间 合作，包括研究务虚会、研讨会、研究座谈会和有针对性的试点资金。CB有 利用历史上在集水区优先事项、胃肠道疾病和血液病方面的制度优势， 随着招募工作的开展，我们加强了对乳腺癌和烟草相关癌症的研究。CB成员拥有 可分为四个学科主题的专业知识：1)癌症转移和肿瘤 微环境；2)DNA损伤/修复与调控；3)干细胞生物学；4)细胞信号通路。

CANCER BIOLOGY: ABSTRACT The Cancer Biology (CB) program represents basic science initiatives of The University of Kansas Cancer Center (KUCC), unified by member utilization of molecular, biochemical, and model organism and cell-based approaches to study the aberrant behavior of cancer cells. The CB scientific goal is to support KUCC’s strategic plan by discerning the molecular mechanisms that define normal and neoplastic cell growth to identify and characterize cells, molecules, pathways, and processes that are involved in tumor growth and progression, which can serve as useful biomarkers or as new cellular targets for cancer prevention and therapeutics, particularly in tumors important to the KUCC’s catchment area. To accomplish this, CB aims to catalyze collaborations that promote basic discoveries that can be translated from bench-to-bedside. CB has 46 full and 14 associate members representing four campuses: the University of Kansas Medical Center (KUMC) (67%), University of Kansas – Lawrence (KU-L) (10%), Children’s Mercy (CM) (5%), and Stowers Institute for Medical Research (Stowers) (18%). In 2020, CB garnered over $9M in cancer-related, peer-reviewed funding of which $1.2M was from NCI and $6.9M was from other institutes at NIH. From 2016- 2020, members published 880 cancer-relevant, peer-reviewed papers. Of these publications, 13% were in high-impact journals (JIF >10) and the average impact factor for all 880 publications is 6.1. Since renewing the CCSG in 2017, CB program cohesion and integration have increased, with 21% of the publications during the funding cycle resulting from inter-programmatic interactions (up from 20% in 2016) and 29% from intra- programmatic interactions (up from 21% in 2016). CB members are well-integrated into the national and international scientific community as evident by over half of the publications (51%) including authors from other institutions and 23% including authors from other NCI-designated cancer centers. CB is jointly led by Kristi Neufeld (KU-L), Linheng Li (Stowers), Sufi Thomas (KUMC), and Tomoo Iwakuma (CM), who bring complementary scientific expertise in cell biology, stem cell biology, biochemistry, translational research, leadership experience, and diverse institutional representation. Shrikant Anant is Associate Director for Basic Science. CB leadership employs a variety of mechanisms to foster intra- and inter-programmatic collaborations, including research retreats, seminars, research symposia, and targeted pilot funding. CB has taken advantage of historical institutional strengths in catchment area priorities, GI, and hematologic cancers, with recruitment strengthening our research on breast and tobacco-related cancers. CB members have expertise that can be organized into four discipline-based themes: 1) cancer metastasis and tumor microenvironment; 2) DNA damage/repair and regulation; 3) stem cell biology; and 4) cell signaling pathways.